MedTrace Logo

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

NCT00673881 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-04-20

Study results available
· View outcomes & findings →

Summary

The objectives of the study are:

1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein \[HDL\] cholesterol levels and elevated triglyceride \[TG\] concentrations).
2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL.
3. To obtain pilot data for power calculations for subsequent comparative study.

Conditions

Interventions

DRUG

choline fenofibrate

135 mg choline fenofibrate daily(oral, capsule)

Sponsors & Collaborators

  • Radiant Research

    lead OTHER

Principal Investigators

  • Michael H Davidson, MD,FACC · Radiant Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00673881 on ClinicalTrials.gov